Association Between Immune-Related Adverse Events and Efficacy and Changes in the Relative Eosinophil Count Among Patients with Advanced Urothelial Carcinoma Treated by Pembrolizumab.

Nobuki FurubayashiAkinori MinatoTakahito NegishiNaotaka SakamotoYoohyun SongYoshifumi HoriToshihisa TomodaMirii HaradaShingo TamuraAkihiro MiuraHiroki KomoriKentaro KuroiwaNarihito SekiNaohiro FujimotoMotonobu Nakamura

Published in: Cancer management and research (2022)

Patients with irAEs showed a significantly better survival compared to patients without irAEs in advanced UC treated with pembrolizumab. An increased posttreatment REC may be a marker predicting improved clinical outcomes and it had no significant relationship with the incidence of irAEs.

Keyphrases

newly diagnosed
end stage renal disease
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
risk factors
free survival